| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 48 | 2021 | 1172 | 1.720 |
Why?
|
| Lung Neoplasms | 56 | 2023 | 2463 | 1.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 43 | 2021 | 2642 | 1.090 |
Why?
|
| Advisory Committees | 1 | 2022 | 94 | 0.740 |
Why?
|
| Medical Oncology | 1 | 2022 | 408 | 0.580 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 3 | 2009 | 13 | 0.570 |
Why?
|
| Vinblastine | 13 | 2002 | 100 | 0.510 |
Why?
|
| Paclitaxel | 15 | 2008 | 498 | 0.490 |
Why?
|
| Ifosfamide | 12 | 2003 | 48 | 0.420 |
Why?
|
| Combined Modality Therapy | 26 | 2010 | 1773 | 0.370 |
Why?
|
| Adenocarcinoma | 12 | 2016 | 1215 | 0.360 |
Why?
|
| Esophageal Neoplasms | 7 | 2010 | 346 | 0.350 |
Why?
|
| Survival Rate | 22 | 2021 | 1986 | 0.310 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2019 | 1105 | 0.310 |
Why?
|
| Cisplatin | 15 | 2010 | 611 | 0.310 |
Why?
|
| Antineoplastic Agents | 12 | 2019 | 2422 | 0.300 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 13 | 2008 | 169 | 0.280 |
Why?
|
| Antineoplastic Agents, Phytogenic | 8 | 2008 | 276 | 0.280 |
Why?
|
| Camptothecin | 4 | 2008 | 204 | 0.260 |
Why?
|
| Neoplasm Staging | 22 | 2019 | 2081 | 0.260 |
Why?
|
| Aged | 53 | 2021 | 20964 | 0.250 |
Why?
|
| Nucleosides | 1 | 2006 | 23 | 0.240 |
Why?
|
| Biomarkers, Tumor | 4 | 2023 | 1665 | 0.230 |
Why?
|
| Middle Aged | 55 | 2021 | 28363 | 0.220 |
Why?
|
| Carcinoma, Small Cell | 3 | 2004 | 137 | 0.220 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2020 | 244 | 0.210 |
Why?
|
| Radiosurgery | 2 | 2021 | 316 | 0.210 |
Why?
|
| Humans | 74 | 2023 | 96127 | 0.200 |
Why?
|
| Female | 60 | 2021 | 50063 | 0.180 |
Why?
|
| Male | 58 | 2021 | 45870 | 0.180 |
Why?
|
| Adult | 48 | 2021 | 28718 | 0.180 |
Why?
|
| United States Food and Drug Administration | 1 | 2022 | 147 | 0.180 |
Why?
|
| Taxoids | 7 | 2012 | 131 | 0.180 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 50 | 0.170 |
Why?
|
| Carboplatin | 8 | 2008 | 331 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 107 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2008 | 1973 | 0.170 |
Why?
|
| Salvage Therapy | 2 | 2019 | 238 | 0.160 |
Why?
|
| Capecitabine | 1 | 2020 | 99 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 1998 | 138 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 19 | 0.150 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 3927 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2021 | 647 | 0.150 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2019 | 23 | 0.150 |
Why?
|
| Precision Medicine | 2 | 2016 | 451 | 0.150 |
Why?
|
| Remission Induction | 10 | 2011 | 769 | 0.150 |
Why?
|
| Infusions, Intravenous | 5 | 2002 | 423 | 0.150 |
Why?
|
| Aged, 80 and over | 15 | 2021 | 7232 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2019 | 161 | 0.140 |
Why?
|
| Benzamides | 1 | 2019 | 248 | 0.140 |
Why?
|
| Treatment Outcome | 17 | 2014 | 9173 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 209 | 0.140 |
Why?
|
| Blood Group Incompatibility | 2 | 2009 | 22 | 0.130 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2015 | 90 | 0.130 |
Why?
|
| Piperazines | 1 | 2019 | 296 | 0.130 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 310 | 0.130 |
Why?
|
| Pneumonectomy | 4 | 2011 | 220 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2012 | 1469 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2012 | 611 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 763 | 0.120 |
Why?
|
| Prognosis | 9 | 2021 | 4033 | 0.120 |
Why?
|
| Interferon-alpha | 4 | 1997 | 215 | 0.110 |
Why?
|
| Carcinoma | 1 | 1998 | 449 | 0.110 |
Why?
|
| Fluorouracil | 9 | 1998 | 555 | 0.110 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 3147 | 0.110 |
Why?
|
| Radiotherapy, Image-Guided | 2 | 2012 | 62 | 0.110 |
Why?
|
| Mesna | 2 | 2008 | 9 | 0.100 |
Why?
|
| Disease Progression | 6 | 2023 | 1568 | 0.100 |
Why?
|
| Drug Administration Schedule | 12 | 2003 | 873 | 0.100 |
Why?
|
| Exanthema | 1 | 2014 | 41 | 0.100 |
Why?
|
| Blood Proteins | 1 | 2014 | 151 | 0.100 |
Why?
|
| Leucovorin | 8 | 1998 | 227 | 0.100 |
Why?
|
| Neoplasm Metastasis | 4 | 2012 | 1103 | 0.100 |
Why?
|
| Organoplatinum Compounds | 2 | 2004 | 100 | 0.090 |
Why?
|
| Ketones | 1 | 2012 | 14 | 0.090 |
Why?
|
| Furans | 1 | 2012 | 19 | 0.090 |
Why?
|
| Genetic Testing | 1 | 2016 | 565 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 39 | 0.090 |
Why?
|
| Glutamates | 2 | 2014 | 90 | 0.090 |
Why?
|
| Proteomics | 1 | 2014 | 269 | 0.090 |
Why?
|
| Guanine | 2 | 2014 | 207 | 0.080 |
Why?
|
| Sirolimus | 1 | 2012 | 177 | 0.080 |
Why?
|
| Recombinant Proteins | 6 | 2008 | 1034 | 0.080 |
Why?
|
| United States | 2 | 2022 | 7767 | 0.080 |
Why?
|
| Thigh | 1 | 1990 | 41 | 0.080 |
Why?
|
| ErbB Receptors | 4 | 2015 | 513 | 0.080 |
Why?
|
| Neutropenia | 6 | 2008 | 218 | 0.080 |
Why?
|
| Cladribine | 1 | 2009 | 35 | 0.070 |
Why?
|
| Transfusion Reaction | 1 | 2009 | 16 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1990 | 126 | 0.070 |
Why?
|
| Disease-Free Survival | 5 | 2014 | 1195 | 0.070 |
Why?
|
| Splenectomy | 1 | 2009 | 82 | 0.070 |
Why?
|
| Lymphocyte Subsets | 1 | 2009 | 69 | 0.070 |
Why?
|
| Transplantation | 1 | 2009 | 38 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 81 | 0.070 |
Why?
|
| Vidarabine | 1 | 2009 | 146 | 0.070 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2009 | 70 | 0.070 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2009 | 109 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2008 | 91 | 0.070 |
Why?
|
| Rituximab | 1 | 2009 | 133 | 0.070 |
Why?
|
| Survival Analysis | 7 | 2011 | 1546 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 5 | 2011 | 270 | 0.070 |
Why?
|
| Drug Tolerance | 3 | 1996 | 64 | 0.070 |
Why?
|
| Mutation | 5 | 2023 | 4374 | 0.070 |
Why?
|
| Quinazolines | 1 | 2008 | 216 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 294 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2009 | 1023 | 0.060 |
Why?
|
| Thoracic Neoplasms | 2 | 1998 | 69 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2009 | 171 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2007 | 340 | 0.060 |
Why?
|
| Histocompatibility | 1 | 2006 | 66 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2006 | 70 | 0.060 |
Why?
|
| Dacarbazine | 1 | 2006 | 101 | 0.060 |
Why?
|
| Filgrastim | 3 | 2008 | 59 | 0.060 |
Why?
|
| Radiotherapy Dosage | 4 | 2001 | 482 | 0.050 |
Why?
|
| Gene Amplification | 2 | 2019 | 143 | 0.050 |
Why?
|
| Feasibility Studies | 4 | 2008 | 819 | 0.050 |
Why?
|
| Thionucleotides | 1 | 2004 | 56 | 0.050 |
Why?
|
| Neoplasms | 3 | 1997 | 3250 | 0.050 |
Why?
|
| Cephalexin | 1 | 2003 | 6 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 995 | 0.050 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 1 | 2003 | 20 | 0.050 |
Why?
|
| Brain Neoplasms | 2 | 2008 | 855 | 0.050 |
Why?
|
| Etoposide | 4 | 2008 | 212 | 0.050 |
Why?
|
| Survival | 1 | 2002 | 21 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 209 | 0.050 |
Why?
|
| Time Factors | 3 | 2014 | 5585 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1431 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 944 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2006 | 372 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2021 | 64 | 0.040 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2001 | 35 | 0.040 |
Why?
|
| Pemetrexed | 2 | 2014 | 76 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Ceftizoxime | 1 | 1999 | 3 | 0.040 |
Why?
|
| North America | 1 | 2000 | 199 | 0.040 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 1999 | 6 | 0.040 |
Why?
|
| Cephalosporins | 1 | 1999 | 25 | 0.040 |
Why?
|
| Thrombopoietin | 1 | 1999 | 12 | 0.040 |
Why?
|
| Retrospective Studies | 6 | 2021 | 10286 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 1999 | 39 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 539 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1220 | 0.040 |
Why?
|
| Europe | 1 | 2000 | 349 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2015 | 518 | 0.040 |
Why?
|
| Agranulocytosis | 2 | 1995 | 20 | 0.040 |
Why?
|
| Topotecan | 1 | 1998 | 46 | 0.040 |
Why?
|
| Macrolides | 2 | 2012 | 31 | 0.040 |
Why?
|
| Chemoradiotherapy | 2 | 2011 | 328 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 4671 | 0.030 |
Why?
|
| Esophagus | 1 | 1998 | 111 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 847 | 0.030 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 1995 | 172 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2009 | 2591 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 381 | 0.030 |
Why?
|
| Expectorants | 1 | 1996 | 6 | 0.030 |
Why?
|
| Chicago | 3 | 2014 | 1503 | 0.030 |
Why?
|
| International Agencies | 1 | 2015 | 34 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1996 | 100 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1882 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 1995 | 238 | 0.030 |
Why?
|
| Radiation Dosage | 2 | 2011 | 236 | 0.030 |
Why?
|
| Bone Marrow | 4 | 1998 | 458 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 1994 | 18 | 0.030 |
Why?
|
| Hydroxyurea | 4 | 1995 | 239 | 0.030 |
Why?
|
| Cetuximab | 1 | 2014 | 119 | 0.030 |
Why?
|
| Esophagitis | 3 | 1998 | 43 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2012 | 514 | 0.020 |
Why?
|
| Ethers, Cyclic | 1 | 2012 | 8 | 0.020 |
Why?
|
| Bridged-Ring Compounds | 1 | 2012 | 16 | 0.020 |
Why?
|
| Indoles | 1 | 1994 | 317 | 0.020 |
Why?
|
| Platinum | 1 | 2012 | 67 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2494 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1816 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 886 | 0.020 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 17 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1791 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2003 | 220 | 0.020 |
Why?
|
| Receptors, Growth Factor | 1 | 2011 | 52 | 0.020 |
Why?
|
| Genes, ras | 1 | 2011 | 97 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2001 | 688 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 74 | 0.020 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2011 | 134 | 0.020 |
Why?
|
| Genomics | 1 | 2016 | 855 | 0.020 |
Why?
|
| Whole-Body Counting | 1 | 1989 | 6 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 1989 | 30 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2011 | 201 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1807 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2008 | 5 | 0.020 |
Why?
|
| Hematinics | 1 | 2008 | 11 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2007 | 3107 | 0.020 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2008 | 20 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1989 | 294 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2014 | 1020 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 271 | 0.020 |
Why?
|
| Risk Factors | 2 | 2014 | 5960 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 366 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2007 | 28 | 0.020 |
Why?
|
| Anemia | 1 | 2008 | 137 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1933 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 813 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2008 | 377 | 0.020 |
Why?
|
| Cyclophosphamide | 3 | 1992 | 313 | 0.010 |
Why?
|
| Leukemia | 1 | 1987 | 328 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 1323 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2007 | 328 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 67 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 444 | 0.010 |
Why?
|
| Bryostatins | 1 | 2003 | 14 | 0.010 |
Why?
|
| Lactones | 1 | 2003 | 27 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 7025 | 0.010 |
Why?
|
| Premedication | 1 | 2003 | 58 | 0.010 |
Why?
|
| Sex Factors | 2 | 2000 | 1133 | 0.010 |
Why?
|
| Smoking | 2 | 2000 | 653 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 281 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2001 | 79 | 0.010 |
Why?
|
| Radiation Pneumonitis | 1 | 2001 | 23 | 0.010 |
Why?
|
| Lung | 1 | 1987 | 1382 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 1998 | 1178 | 0.010 |
Why?
|
| Methotrexate | 2 | 1992 | 249 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2003 | 369 | 0.010 |
Why?
|
| Doxorubicin | 2 | 1992 | 304 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1990 | 136 | 0.010 |
Why?
|
| Creatinine | 1 | 2001 | 299 | 0.010 |
Why?
|
| Spirometry | 1 | 2000 | 78 | 0.010 |
Why?
|
| Coombs Test | 1 | 1999 | 8 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2000 | 136 | 0.010 |
Why?
|
| Pilot Projects | 2 | 1994 | 938 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 713 | 0.010 |
Why?
|
| Hemolysis | 1 | 1999 | 63 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1989 | 2781 | 0.010 |
Why?
|
| Antigen-Antibody Complex | 1 | 1999 | 89 | 0.010 |
Why?
|
| Platelet Count | 1 | 1999 | 97 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1999 | 127 | 0.010 |
Why?
|
| Antibodies | 1 | 1999 | 357 | 0.010 |
Why?
|
| Thorax | 1 | 1997 | 80 | 0.010 |
Why?
|
| Isotretinoin | 1 | 1997 | 20 | 0.010 |
Why?
|
| Antidotes | 1 | 1997 | 24 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1998 | 599 | 0.010 |
Why?
|
| Leukopenia | 1 | 1997 | 68 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1999 | 327 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1997 | 134 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1997 | 318 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 1316 | 0.010 |
Why?
|
| Incidence | 1 | 2000 | 1715 | 0.010 |
Why?
|
| Age Factors | 1 | 2000 | 1963 | 0.010 |
Why?
|
| Esophagogastric Junction | 1 | 1995 | 35 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1996 | 163 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1829 | 0.010 |
Why?
|
| Cyclohexenes | 1 | 1994 | 5 | 0.010 |
Why?
|
| Benzofurans | 1 | 1994 | 9 | 0.010 |
Why?
|
| Palliative Care | 1 | 1996 | 273 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 1994 | 79 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1995 | 315 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1995 | 191 | 0.010 |
Why?
|
| Postoperative Care | 1 | 1995 | 239 | 0.010 |
Why?
|
| Research Design | 1 | 1997 | 631 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1994 | 156 | 0.010 |
Why?
|
| Procarbazine | 1 | 1992 | 38 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1994 | 179 | 0.010 |
Why?
|
| Vincristine | 1 | 1990 | 113 | 0.000 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1994 | 935 | 0.000 |
Why?
|
| Bleomycin | 1 | 1990 | 103 | 0.000 |
Why?
|
| Chi-Square Distribution | 1 | 1990 | 363 | 0.000 |
Why?
|
| Vindesine | 1 | 1989 | 9 | 0.000 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1989 | 49 | 0.000 |
Why?
|
| Mediastinal Neoplasms | 1 | 1989 | 46 | 0.000 |
Why?
|
| Radiography, Abdominal | 1 | 1989 | 68 | 0.000 |
Why?
|
| Prednisone | 1 | 1990 | 258 | 0.000 |
Why?
|
| Cytarabine | 1 | 1990 | 225 | 0.000 |
Why?
|
| Radionuclide Imaging | 1 | 1989 | 217 | 0.000 |
Why?
|
| Thiotepa | 1 | 1989 | 33 | 0.000 |
Why?
|
| Melphalan | 1 | 1989 | 100 | 0.000 |
Why?
|
| Actuarial Analysis | 1 | 1987 | 66 | 0.000 |
Why?
|
| Proportional Hazards Models | 1 | 1990 | 901 | 0.000 |
Why?
|
| Multivariate Analysis | 1 | 1990 | 1010 | 0.000 |
Why?
|
| Karyotyping | 1 | 1987 | 257 | 0.000 |
Why?
|
| Radiography, Thoracic | 1 | 1989 | 334 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1989 | 418 | 0.000 |
Why?
|
| Acute Disease | 1 | 1987 | 872 | 0.000 |
Why?
|